Go to full publication
MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment.
September 1, 2024
Allergy
- Home
-
Publications
Publications
Active filters
Add filters (0)
2 results
COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
December 1, 2021
Eur Respir J
Abstract BACKGROUND Asthma is a heterogeneous syndrome substantiating the urgent requirement for endotype-specific biomarkers. Dysbalance of fibrosis and fibrolysis in asthmatic lung tissue leads to reduced levels of the inflammation-protective collagen 4 (COL4A3). OBJECTIVE To delineate the degradation of COL4A3 in allergic airway inflammation and evaluate the resultant product as a biomarker for anti-IgE therapy […]